Drug delivery system based on cyclodextrin-naproxen inclusion complex incorporated in electrospun polycaprolactone nanofibers

Simple item page
buir.contributor.authorUyar, Tamer
buir.contributor.orcidUyar, Tamer|0000-0002-3989-4481
dc.citation.epage21en_US
dc.citation.spage15en_US
dc.citation.volumeNumber115en_US
dc.contributor.authorCanbolat, M. F.en_US
dc.contributor.authorCelebioglu A.en_US
dc.contributor.authorUyar, Tameren_US
dc.date.accessioned2016-02-08T10:58:12Z
dc.date.available2016-02-08T10:58:12Z
dc.date.issued2014en_US
dc.departmentInstitute of Materials Science and Nanotechnology (UNAM)en_US
dc.departmentNanotechnology Research Center (NANOTAM)en_US
dc.description.abstractIn this study, we select naproxen (NAP) as a reference drug and electrospun poly (e-caprolactone) (PCL) nanofibers as a fibrous matrix for our drug-delivery system. NAP was complexed with beta-cyclodextrin (βCD) to form inclusion complex (NAP-βCD-IC) and then NAP-βCD-IC was incorporated into PCL nanofibers via electrospinning. The incorporation of NAP without CD-IC into electrospun PCL was also carried out for a comparative study. Our aim is to analyze the release profiles of NAP from PCL/NAP and PCL/NAP-βCD-IC nanofibers and we investigate the effect of CD-IC on the release behavior of NAP from the nanofibrous PCL matrix. The characterization of NAP-βCD-IC and the presence of CD-IC in PCL/NAP-βCD-IC nanofibers were studied by FTIR, XRD, TGA, NMR and SEM. The SEM imaging of the electrospun PCL/NAP and PCL/NAP-βCD-IC nanofibers reveal that the average fiber diameter of these nanofibers is around 300. nm, in addition, the aggregates of CD-IC in PCL/NAP-βCD-IC nanofibers is observed. The release study of NAP in buffer solution elucidate that the PCL/NAP-βCD-IC nanofibers have higher release amount of NAP than the PCL/NAP nanofibers due to the solubility enhancement of NAP by CD-IC.en_US
dc.description.provenanceMade available in DSpace on 2016-02-08T10:58:12Z (GMT). No. of bitstreams: 1 bilkent-research-paper.pdf: 70227 bytes, checksum: 26e812c6f5156f83f0e77b261a471b5a (MD5) Previous issue date: 2014en_US
dc.identifier.doi10.1016/j.colsurfb.2013.11.021en_US
dc.identifier.issn0927-7765
dc.identifier.urihttp://hdl.handle.net/11693/26315
dc.language.isoEnglishen_US
dc.publisherElsevieren_US
dc.relation.isversionofhttp://dx.doi.org/10.1016/j.colsurfb.2013.11.021en_US
dc.source.titleColloids and Surfaces B: Biointerfacesen_US
dc.subjectCyclodextrinen_US
dc.subjectDrugen_US
dc.subjectInclusion complexen_US
dc.subjectNanofibersen_US
dc.subjectNaproxenen_US
dc.subjectReleaseen_US
dc.subjectCyclodextrinsen_US
dc.subjectDrug deliveryen_US
dc.subjectPolycaprolactoneen_US
dc.subjectAverage fiber diametersen_US
dc.subjectDrugen_US
dc.subjectDrug-delivery systemsen_US
dc.subjectInclusion complexen_US
dc.subjectNaproxensen_US
dc.subjectPoly(ecaprolactone) (PCL)en_US
dc.subjectReleaseen_US
dc.subjectSolubility enhancementen_US
dc.subjectNanofibersen_US
dc.subjectBeta cyclodextrinen_US
dc.subjectBufferen_US
dc.subjectNanofiberen_US
dc.subjectNaproxenen_US
dc.subjectPolycaprolactoneen_US
dc.subjectPolycaprolactone nanofiberen_US
dc.subjectUnclassified drugen_US
dc.subjectBeta cyclodextrinen_US
dc.subjectBeta cyclodextrin derivativeen_US
dc.subjectNanofiberen_US
dc.subjectNaproxenen_US
dc.subjectPolycaprolactoneen_US
dc.subjectPolyesteren_US
dc.subjectArticleen_US
dc.subjectComplex formationen_US
dc.subjectControlled studyen_US
dc.subjectDrug delivery systemen_US
dc.subjectDrug releaseen_US
dc.subjectDrug solubilityen_US
dc.subjectElectrospinningen_US
dc.subjectInfrared spectroscopyen_US
dc.subjectParticle sizeen_US
dc.subjectPhysical chemistryen_US
dc.subjectPriority journalen_US
dc.subjectProton nuclear magnetic resonanceen_US
dc.subjectScanning electron microscopyen_US
dc.subjectThermogravimetryen_US
dc.subjectX ray diffractionen_US
dc.subjectChemistryen_US
dc.subjectHigh performance liquid chromatographyen_US
dc.subjectNuclear magnetic resonance spectroscopyen_US
dc.subjectProceduresen_US
dc.subjectSolubilityen_US
dc.subjectTissue engineeringen_US
dc.subjectUltrastructureen_US
dc.subjectUltraviolet spectrophotometryen_US
dc.subjectBeta-Cyclodextrinsen_US
dc.subjectChromatography, High Pressure Liquiden_US
dc.subjectDrug Delivery Systemsen_US
dc.subjectMagnetic Resonance Spectroscopyen_US
dc.subjectNanofibersen_US
dc.subjectNaproxenen_US
dc.subjectPolyestersen_US
dc.subjectSolubilityen_US
dc.subjectSpectrophotometry, Ultravioleten_US
dc.subjectSpectroscopy, Fourier Transform Infrareden_US
dc.subjectThermogravimetryen_US
dc.subjectTissue Engineeringen_US
dc.subjectX-Ray Diffractionen_US
dc.titleDrug delivery system based on cyclodextrin-naproxen inclusion complex incorporated in electrospun polycaprolactone nanofibersen_US
dc.typeArticleen_US

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Drug delivery system based on cyclodextrin-naproxen inclusion complex incorporated in electrospun polycaprolactone nanofibers.pdf
Size:
1.58 MB
Format:
Adobe Portable Document Format
Description:
Full printable version
Download

Collections

Scholarly Publications - UNAM
Scholarly Publications - NANOTAM